Homeland Security TV Features Generex Executive to Discuss H1N1 Preparedness and...

Homeland Security TV Features Generex Executive to Discuss H1N1 Preparedness and
Related Biological Security Issues

WORCESTER, Mass., Oct. 5, 2009 (GLOBE NEWSWIRE) -- Dr. Eric von Hofe, PhD,
President of Antigen Express, Inc. (www.antigenexpress.com), the wholly-owned
immunotherapeutics subsidiary of Generex Biotechnology Corporation (Nasdaq:GNBT)
(www.generex.com), is currently featured on the Homeland Security Television
Channel, an on-demand television network dedicated to homeland security and
global development. The segment can be viewed online at www.hstvchannel.com and
will be available later today at www.generex.com.

Interviewed by program host and executive producer Dan Verton in an episode
titled "2009 Influenza Pandemic Preparedness," Dr. von Hofe discussed the
shifting types of flu strains, resulting in new vaccines every season, and
distinguished vaccines from antiviral agents and methods that would help cut
down on the transmission of the H1N1 virus.

Antigen Express is developing novel immunotherapeutic and prophylactic vaccines
for influenza. The Company has obtained broad and strong patent coverage for its
proprietary platform technologies, which would manufacture modified peptide
vaccines by an entirely synthetic process, in contrast with egg-based or
cell-culture-based vaccines that require expensive, extensive and
labor-intensive manipulation.

"The H1N1 virus has tremendous infectivity in people and was cause for alarm,"
noted von Hofe. "While H5N1 avian influenza has had a limited impact on humans,
the H1N1 virus has shown itself to be highly contagious in humans and might come
back."

Dr. von Hofe described best practices for steering clear of the virus and also
provided commentary on the new clinical trials approved by the FDA that look at
a one-dosage vaccination that would benefit the most vulnerable age
demographics, including pregnant women and children six months of age through 24
years of age.

Antigen Express's entirely synthetic vaccine platform reduces cost and increases
both the speed and quantity of production. This is of particular benefit in
meeting rapidly emerging viral threats such as the potentially pandemic H5N1
avian and H1N1 swine influenzas. Vaccines developed using this platform are
already in various stage clinical trials for avian flu, as well as prostate,
breast and ovarian cancers.

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug
delivery systems and technologies. Generex has developed a proprietary platform
technology for the delivery of drugs into the human body through the oral cavity
(with no deposit in the lungs). The Company's proprietary liquid formulations
allow drugs typically administered by injection to be absorbed into the body by
the lining of the inner mouth using the Company's proprietary RapidMist(TM)
device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)),
which is available for sale in India, Lebanon, Algeria, and Ecuador for the
treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical
trials at several sites around the world. Antigen Express, Inc. is a wholly
owned subsidiary of Generex. The core platform technologies of Antigen Express
comprise immunotherapeutics for the treatment of malignant, infectious,
allergic, and autoimmune diseases. For more information, visit the Generex
website at www.generex.com or the Antigen Express website at
www.antigenexpress.com.

The Generex Biotechnology Corp. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3831

Safe Harbor Statement

This release and oral statements made from time to time by Generex
representatives in respect of the same subject matter may contain
"forward-looking statements" within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by
introductory words such as "expects," "plans," "intends," "believes," "will,"
"estimates," "forecasts," "projects," or words of similar meaning, and by the
fact that they do not relate strictly to historical or current facts.
Forward-looking statements frequently are used in discussing potential product
applications, potential collaborations, product development activities, clinical
studies, regulatory submissions and approvals, and similar operating matters.
Many factors may cause actual results to differ from forward-looking statements,
including inaccurate assumptions and a broad variety of risks and uncertainties,
some of which are known and others of which are not. Known risks and
uncertainties include those identified from time to time in the reports filed by
Generex with the Securities and Exchange Commission, which should be considered
together with any forward-looking statement. No forward-looking statement is a
guarantee of future results or events, and one should avoid placing undue
reliance on such statements. Generex undertakes no obligation to update publicly
any forward-looking statements, whether as a result of new information, future
events or otherwise. Generex cannot be sure when or if it will be permitted by
regulatory agencies to undertake additional clinical trials or to commence any
particular phase of clinical trials. Because of this, statements regarding the
expected timing of clinical trials cannot be regarded as actual predictions of
when Generex will obtain regulatory approval for any "phase" of clinical trials.
Generex claims the protection of the safe harbor for forward-looking statements
that is contained in the Private Securities Litigation Reform Act.

-0-
CONTACT: American Capital Ventures, Inc.
Investor Relations Contact:
Howard Gostfrand
1-877-918-0774

Beckerman Public Relations
Media Contact:
Jerry Schranz
201-465-8020